A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia
Expert Review of Clinical Pharmacology · 2023
DOI: 10.1080/17512433.2023.2223970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Anshul Vagrecha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New Hyde Park, NY, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Hypersensitivity, Erwinia, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pegylated form of E. coli derived asparaginase (PEG) is a crucial component of pediatric ALL therapy. Patients who develop a hypersensitivity (HSR) reaction with PEG receive an alternative form - Erwinia asparaginase (EA). However, an international shortage in 2017 had made it challenging to treat these patients. We have developed a comprehensive strategy to address this need. PATIENTS AND METHODS: This is a single center, retrospective analysis. All patients receiving PEG were premedicated to reduce infusion reactions. Patients who developed HSR underwent PEG desensitization. Patients were compared to historic controls. RESULTS: Fifty-six patients were treated within the study period. There was no difference in the frequency of reactions before and after the adoption of universal premedication (p = 0.78). Eight patients (14.2%) developed either ≥ Grade 2 HSR or silent inactivation and 5 patients (62.5%) successfully underwent desensitization. The remaining three patients received EA asparaginase. This intervention led to a decrease in PEG substitution, with 3 patients (5.3%) requiring EA compared to 8 patients (15.09%) in the pre-intervention period. (p = 0.11) PEG desensitization was more cost effective than EA administration. CONCLUSION: PEG desensitization is a safe, cost effective, and practical alternative in children with ALL and a Grade 2 or higher HSR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New Hyde Park, NY, USA.
- Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
ORCID-Profile: Anshul Vagrecha
Zitieren
APA
Vagrecha, A., Tao, V., Corless, R., Colon, C., Redner, A., & Atlas, M. (2023). A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2223970
Vancouver
Vagrecha A, Tao V, Corless R, Colon C, Redner A, Atlas M. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2223970
BibTeX
@article{Vagrecha2023,
author = {Vagrecha, Anshul and Tao, Vincent and Corless, Rosemarie and Colon, Cassandra and Redner, Arlene and Atlas, Mark},
title = {A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
doi = {10.1080/17512433.2023.2223970}
}
EUVIMED